Pharmacological aspects of submaxillary gland secretion in cystic fibrosis.
D000328:Adult; D001341:Autonomic Nervous System / Q000187:drug effects*; D001949:Bretylium Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D002118:Calcium / Q000032:analysis; D002648:Child; D003550:Cystic Fibrosis / Q000503:physiopathology*; D005643:Fucose / Q000032:analysis; D006145:Guanethidine / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008688:Methacholine Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D009566:Nitrates / Q000494:pharmacology; D009584:Nitrogen / Q000032:analysis; D010275:Parasympathetic Nervous System / Q000187:drug effects; D011188:Potassium / Q000032:analysis; D012463:Saliva / Q000032:analysis / Q000187:drug effects; D012964:Sodium / Q000032:analysis / Q000494:pharmacology; D013268:Stimulation, Chemical; D013363:Submandibular Gland / Q000294:innervation / Q000378:metabolism*; D013564:Sympathetic Nervous System / Q000187:drug effects
D001949:Bretylium Compounds; D008688:Methacholine Compounds; D009566:Nitrates; D005643:Fucose; D012964:Sodium; D009584:Nitrogen; D011188:Potassium; D002118:Calcium; D006145:Guanethidine